[go: up one dir, main page]

WO2008156094A1 - ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 - Google Patents

ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 Download PDF

Info

Publication number
WO2008156094A1
WO2008156094A1 PCT/JP2008/061087 JP2008061087W WO2008156094A1 WO 2008156094 A1 WO2008156094 A1 WO 2008156094A1 JP 2008061087 W JP2008061087 W JP 2008061087W WO 2008156094 A1 WO2008156094 A1 WO 2008156094A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
active ingredient
inhibitor containing
pyridazinone derivative
pde inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/061087
Other languages
English (en)
French (fr)
Inventor
Yasushi Kohno
Koji Ochiai
Satoshi Takita
Akihiko Kojima
Tomohiko Eiraku
Tetsuya Kishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Priority to EP08765704A priority Critical patent/EP2168959A1/en
Priority to JP2009520496A priority patent/JPWO2008156094A1/ja
Priority to US12/452,172 priority patent/US20100160335A1/en
Priority to CA002692248A priority patent/CA2692248A1/en
Publication of WO2008156094A1 publication Critical patent/WO2008156094A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ホスホジエステラーゼ阻害作用を有する医薬品として有用な下記一般式（１）で表される新規ピリダジノン誘導体を提供すること。
PCT/JP2008/061087 2007-06-19 2008-06-18 ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 Ceased WO2008156094A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08765704A EP2168959A1 (en) 2007-06-19 2008-06-18 Pyridazinone derivative and pde inhibitor containing the same as active ingredient
JP2009520496A JPWO2008156094A1 (ja) 2007-06-19 2008-06-18 ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US12/452,172 US20100160335A1 (en) 2007-06-19 2008-06-18 Pyridazinone derivative and pde inhibitor containing the same as active ingredient
CA002692248A CA2692248A1 (en) 2007-06-19 2008-06-18 Pyridazinone derivative and pde inhibitor containing the same as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007160955 2007-06-19
JP2007-160955 2007-06-19

Publications (1)

Publication Number Publication Date
WO2008156094A1 true WO2008156094A1 (ja) 2008-12-24

Family

ID=40156253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061087 Ceased WO2008156094A1 (ja) 2007-06-19 2008-06-18 ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤

Country Status (5)

Country Link
US (1) US20100160335A1 (ja)
EP (1) EP2168959A1 (ja)
JP (1) JPWO2008156094A1 (ja)
CA (1) CA2692248A1 (ja)
WO (1) WO2008156094A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117926A1 (en) * 2009-04-07 2010-10-14 Schering Corporation Substituted triazolopyridines and analogs thereof
JP2012512192A (ja) * 2008-12-19 2012-05-31 レオ ファーマ アクティーゼルスカブ 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体
EP2719686A1 (en) * 2010-03-12 2014-04-16 Nippon Soda Co., Ltd. Process to halogenate a picoline derivative
JP2019506432A (ja) * 2016-03-04 2019-03-07 大塚製薬株式会社 ５−メチル−６−フェニル−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658821C (en) 2006-07-25 2014-10-21 Cephalon, Inc. Pyridizinone derivatives and uses thereof to treat diseases, disorders and/or conditions that may be mediated or modulated by inhibition of h3 receptors
MX363732B (es) 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Compuestos antivirales.
SG192078A1 (en) 2011-02-03 2013-08-30 Lupin Ltd Pyrrole derivatives used as modulators of alpha7 nachr
BR112013025128A2 (pt) 2011-03-31 2017-02-14 Lupin Ltd derivados de pirrol como moduladores de receptor de acetilcolina nicotínico para uso no tratamento de distúrbios neurodegenenerativos tal como doença de alzheimer e doença de parkinson
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
CN104478809B (zh) * 2014-11-14 2016-08-17 成都新恒创药业有限公司 一种左西孟旦杂质及其制备和检测方法
CN104530113A (zh) * 2014-12-22 2015-04-22 上海树农化工有限公司 邻氟苯甲酸类化合物及其制备方法
CN106905233A (zh) * 2016-08-31 2017-06-30 湖南大学 一种5‑位炔基化8‑酰胺基喹啉类化合物及其一锅法制备方法
CN106938985B (zh) * 2016-08-31 2020-05-05 湖南大学 一种5-位烯基化8-酰胺基喹啉类化合物及其一锅法制备方法
CN106938984B (zh) * 2016-08-31 2020-05-05 湖南大学 一种5-位取代芳基化/杂环化8-酰胺基喹啉类化合物及其一锅法制备方法
WO2022246072A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection
CN117460734A (zh) 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2007119397A (ja) * 2005-10-28 2007-05-17 Kyorin Pharmaceut Co Ltd ピラゾロピリジン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2008024599A (ja) * 2006-07-18 2008-02-07 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体、それらを有効成分とするｐｄｅ阻害剤及び医薬
WO2008029882A1 (en) * 2006-09-07 2008-03-13 Kyorin Pharmaceutical Co., Ltd. 2-alkyl-6-(pyrazolopyridin-4-yl)pyridazinone derivative, addition salt thereof, and pde inhibitor comprising the derivative or the salt as active ingredient
JP2008063265A (ja) * 2006-09-06 2008-03-21 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2007119397A (ja) * 2005-10-28 2007-05-17 Kyorin Pharmaceut Co Ltd ピラゾロピリジン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2008024599A (ja) * 2006-07-18 2008-02-07 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体、それらを有効成分とするｐｄｅ阻害剤及び医薬
JP2008063265A (ja) * 2006-09-06 2008-03-21 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2008029882A1 (en) * 2006-09-07 2008-03-13 Kyorin Pharmaceutical Co., Ltd. 2-alkyl-6-(pyrazolopyridin-4-yl)pyridazinone derivative, addition salt thereof, and pde inhibitor comprising the derivative or the salt as active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN DER MEY ET AL.: "Synthesis and Structure-Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids: A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 10, 2003, pages 2008 - 2016, XP008126345 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512192A (ja) * 2008-12-19 2012-05-31 レオ ファーマ アクティーゼルスカブ 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体
WO2010117926A1 (en) * 2009-04-07 2010-10-14 Schering Corporation Substituted triazolopyridines and analogs thereof
TWI397530B (zh) * 2009-04-07 2013-06-01 Merck Sharp & Dohme 經取代的三唑并吡啶及其類似物
US8685967B2 (en) 2009-04-07 2014-04-01 Merck Sharp & Dohme Corp. Substituted triazolopyridines and analogs thereof
EP2719686A1 (en) * 2010-03-12 2014-04-16 Nippon Soda Co., Ltd. Process to halogenate a picoline derivative
US8841458B2 (en) 2010-03-12 2014-09-23 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US8962848B2 (en) 2010-03-12 2015-02-24 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US9000178B2 (en) 2010-03-12 2015-04-07 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US9012653B2 (en) 2010-03-12 2015-04-21 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US9018385B2 (en) 2010-03-12 2015-04-28 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
JP2019506432A (ja) * 2016-03-04 2019-03-07 大塚製薬株式会社 ５−メチル−６−フェニル−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体
US10611731B2 (en) 2016-03-04 2020-04-07 Otsuka Pharmaceutical Co., Ltd. 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative

Also Published As

Publication number Publication date
EP2168959A1 (en) 2010-03-31
CA2692248A1 (en) 2008-12-24
US20100160335A1 (en) 2010-06-24
JPWO2008156094A1 (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2006053255A3 (en) Novel betulin derivatives, preparation thereof and use thereof
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
WO2009107850A3 (en) Fused heterocyclic derivative and use thereof
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2009060835A8 (ja) 新規ユビキリン結合性小分子
WO2008011130A8 (en) Amide compounds
WO2009082134A3 (en) Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
WO2007135527A3 (en) Benzimidazolyl compounds
WO2008096841A1 (ja) 二量化シクロ誘導体
WO2007072153A3 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
WO2009051119A1 (ja) ピリミジルインドリン化合物
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
WO2008093838A1 (ja) スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2008153129A1 (ja) 尿酸値低下剤
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2008156102A1 (ja) ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2006110173A3 (en) Novel compounds
WO2005085236A3 (en) Caspase inhibitors and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08765704

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009520496

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2692248

Country of ref document: CA

Ref document number: 2008765704

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12452172

Country of ref document: US